In recent years, the major advances in the field of NSCLC treatment are the development of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors targeting programmed cell death-1 receptor (PD-1)/ligand (PD-L1) [4], [5]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.